ES2531312T3 - Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos - Google Patents

Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos Download PDF

Info

Publication number
ES2531312T3
ES2531312T3 ES10835166T ES10835166T ES2531312T3 ES 2531312 T3 ES2531312 T3 ES 2531312T3 ES 10835166 T ES10835166 T ES 10835166T ES 10835166 T ES10835166 T ES 10835166T ES 2531312 T3 ES2531312 T3 ES 2531312T3
Authority
ES
Spain
Prior art keywords
transnorsertraline
polymorphs
formulations
salts
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10835166T
Other languages
English (en)
Inventor
Sharon Laughlin
Michael Sizensky
Surendra Singh
Scott Wilkinson
Cai Gu Huang
Philip Bonasia
Souza Susan D
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2531312T3 publication Critical patent/ES2531312T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Una composición farmacéutica que comprende, como el único ingrediente activo, hidrocloruro de transnorsertralina o su solvato, y manitol, en donde la composición comprende al menos 10% en peso de manitol, conteniendo dicho manitol menos de 0,1% en peso de manosa.
ES10835166T 2009-12-04 2010-12-03 Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos Active ES2531312T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26686409P 2009-12-04 2009-12-04
PCT/US2010/058831 WO2011069032A2 (en) 2009-12-04 2010-12-03 Formulations, salts and polymorphs of transnorsertraline and uses thereof

Publications (1)

Publication Number Publication Date
ES2531312T3 true ES2531312T3 (es) 2015-03-12

Family

ID=44115510

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10835166T Active ES2531312T3 (es) 2009-12-04 2010-12-03 Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos

Country Status (20)

Country Link
US (3) US8957114B2 (es)
EP (2) EP2937083B1 (es)
JP (2) JP5766713B2 (es)
KR (1) KR101755743B1 (es)
CN (2) CN102740842B (es)
AU (2) AU2010325894B2 (es)
BR (1) BR112012013325B8 (es)
CA (1) CA2782240A1 (es)
DK (1) DK2506842T3 (es)
ES (1) ES2531312T3 (es)
HK (2) HK1216986A1 (es)
IL (2) IL219963A (es)
MX (2) MX339619B (es)
NZ (1) NZ600107A (es)
PL (1) PL2506842T3 (es)
PT (1) PT2506842E (es)
RU (2) RU2578956C2 (es)
SG (1) SG181466A1 (es)
WO (1) WO2011069032A2 (es)
ZA (1) ZA201203621B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
CN101553217A (zh) 2005-07-06 2009-10-07 塞普拉科公司 艾司佐匹克隆与反式4－(3,4－二氯苯基)－1,2,3,4－四氢－n－甲基－1－萘胺或反式4－(3,4－二氯苯基)－1,2,3,4－四氢－1－萘胺的组合以及治疗绝经期和心境障碍、焦虑症和认知障碍的方法
JP6226471B2 (ja) * 2014-02-12 2017-11-08 株式会社リガク 構造精密化装置、方法およびプログラム
CN106660936A (zh) * 2014-05-13 2017-05-10 赛诺维信制药公司 用于治疗adhd的方法和达斯曲林(dasotraline)组合物
US10076503B2 (en) 2014-05-13 2018-09-18 Sunovion Pharmaceuticals Inc. Dosage of dasotraline and method for treatment of ADHD
WO2019143920A1 (en) * 2018-01-19 2019-07-25 Sunovion Pharmaceuticals Inc. Oral dosage forms
CN110310711B (zh) * 2019-06-26 2023-06-27 河南省人造金刚石微粉质量监督检验中心 一种金刚石微粉杂质含量分析结果的不确定度评定方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5213738A (en) 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
JP2003518487A (ja) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク ヒドロゲル駆動型積層薬物製剤
US20060057207A1 (en) * 2001-11-30 2006-03-16 Pfizer Inc Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
CN100584818C (zh) * 2002-09-16 2010-01-27 塞普拉科公司 用反式4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺及其甲酰胺治疗cns病症
JP2006504693A (ja) 2002-09-16 2006-02-09 セプラコア インコーポレーテッド トランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミンによるｃｎｓ障害の治療
EP1542961B1 (en) * 2002-09-16 2013-09-11 Sepracor, Inc. Trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine for use in treatment of cns disorders
CN101553217A (zh) * 2005-07-06 2009-10-07 塞普拉科公司 艾司佐匹克隆与反式4－(3,4－二氯苯基)－1,2,3,4－四氢－n－甲基－1－萘胺或反式4－(3,4－二氯苯基)－1,2,3,4－四氢－1－萘胺的组合以及治疗绝经期和心境障碍、焦虑症和认知障碍的方法
CN101421228B (zh) * 2006-03-31 2014-05-21 塞普拉柯公司 手性酰胺和胺的制备
CA2653498A1 (en) 2006-05-31 2007-12-13 Sepracor Inc. Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide
US7711807B2 (en) * 2006-07-27 2010-05-04 Intel Corporation Selective filtering of exception data units
US20060257475A1 (en) * 2006-08-17 2006-11-16 Boehringer Ingelheim International Gmbh Stable Sertraline Hydrochloride Formulation and Method
CN102573823B (zh) 2009-05-13 2015-01-07 桑诺维恩药品公司 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途

Also Published As

Publication number Publication date
EP2937083B1 (en) 2019-03-27
IL248077B (en) 2020-05-31
CN105125528A (zh) 2015-12-09
KR20120089362A (ko) 2012-08-09
IL248077A0 (en) 2016-11-30
US8957114B2 (en) 2015-02-17
MX2012006226A (es) 2012-06-19
RU2012127777A (ru) 2014-01-20
JP5766713B2 (ja) 2015-08-19
AU2015249065A1 (en) 2015-11-12
BR112012013325A2 (pt) 2017-09-05
EP2506842A4 (en) 2013-05-22
CN102740842A (zh) 2012-10-17
JP2013512921A (ja) 2013-04-18
HK1175692A1 (zh) 2013-07-12
BR112012013325B1 (pt) 2021-05-18
MX339619B (es) 2016-06-02
US20180071230A1 (en) 2018-03-15
US20150196502A1 (en) 2015-07-16
JP2015199763A (ja) 2015-11-12
IL219963A0 (en) 2012-07-31
RU2578956C2 (ru) 2016-03-27
DK2506842T3 (en) 2015-02-23
KR101755743B1 (ko) 2017-07-07
PL2506842T3 (pl) 2015-06-30
US20130116332A1 (en) 2013-05-09
CA2782240A1 (en) 2011-06-09
HK1216986A1 (zh) 2016-12-16
CN102740842B (zh) 2015-07-01
IL219963A (en) 2017-01-31
AU2010325894A1 (en) 2012-06-07
ZA201203621B (en) 2013-08-28
WO2011069032A3 (en) 2011-10-27
EP2506842B1 (en) 2015-01-21
EP2506842A2 (en) 2012-10-10
EP2937083A1 (en) 2015-10-28
RU2016104396A (ru) 2018-11-23
WO2011069032A2 (en) 2011-06-09
AU2015249065B2 (en) 2017-07-20
NZ600107A (en) 2014-10-31
BR112012013325B8 (pt) 2021-05-25
AU2010325894B2 (en) 2015-07-30
MX367327B (es) 2019-08-15
SG181466A1 (en) 2012-07-30
PT2506842E (pt) 2015-03-10

Similar Documents

Publication Publication Date Title
ES2531312T3 (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos
UY32816A (es) Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
CR20140032A (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como modulares de receptores de c5a
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
UY32660A (es) Derivados aminobutricos sustituidos como inhibidores de neprilisina
CU20110207A7 (es) Aril piridinas como inhibidoras de sintasa de aldosterona
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
CO6680667A2 (es) Derivados ester de ácido borónico cíclico y sus usos terapéuticos
CU20110145A7 (es) Derivados de sulfonamida
ECSP12011958A (es) Composiciones farmacéuticas que comprenden ligandos de receptores sigma
UY33075A (es) Derivados de ciclohexano y usos de los mismos
UY31141A1 (es) Compuestos de piperidina y sus usos
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY31922A (es) Compuestos
DOP2011000382A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
CL2014003081A1 (es) Una composicion farmaceutica topica que comprende, en base al peso total de la composicion, 1,5-5 % en peso de terbinafina, 15-35 % en peso de urea y mas que 25 % en peso de agua; y su uso para el tratamiento topico de una infeccion fungica, preferiblemente onicomicosis.
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
CO6361855A2 (es) Derivados de 7-hidroxi-benzoimidazol-4-il-,etanona e inhibidores de cinasa que enlaza pdz que contienen los mismos
CO6351721A2 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
UY33348A (es) Compuestos de furopiridina y usos de los mismos
UY35211A (es) Compuestos tricíclicos
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
UY31637A1 (es) Farmacoforos duales-antagonistas muscarinicos de pde4